The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017.

Bookmark(0)

Few existing studies on the global incidence, prevalence, and burden of disease from psoriasis are of high quality, making reliable data and comparisons difficult to find.We analyzed global psoriasis trends […]

» Read more

Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period.

Bookmark(0)

Psoriasis prevalence is increasing among elderly subjects. Elderly psoriasis patients represent a challenge for dermatologists due to multiple comorbidities, polypharmacy, immune senescence which lead to increased possibility of adverse events, […]

» Read more

Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

Bookmark(0)

Registry studies broadly describing the safety of systemic drugs in psoriasis are needed.To describe the safety findings of systemic drugs (acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, ustekinumab) used […]

» Read more

Risk of Hospitalisation and Death due to Infection in People with Psoriasis: a Population-based Cohort Study using the Clinical Practice Research Datalink.

Bookmark(0)

Psoriasis is associated with risk factors for serious infections, but the independent relationship between psoriasis and serious infection is as yet unclear.To determine whether people with psoriasis have a higher […]

» Read more

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update.

Bookmark(0)

The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), […]

» Read more

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to <12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study.

Bookmark(0)

Limited options are available for treatment of pediatric psoriasis.To evaluate the efficacy and safety of ustekinumab in pediatric psoriasis patients (≥6 to <12 years of age).CADMUS Junior (Jr), a phase […]

» Read more

Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis.

Bookmark(0)

Sex and gender may affect disease prevalence, adverse effects and response to therapy.To analyse sex- and gender differences in psoriasis outpatients.A cross-sectional study was conducted at IDI-IRCCS, Rome, over a […]

» Read more

Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic.

Bookmark(0)

Is psoriasis associated with dementia or cognitive impairment?.Psoriasis is a multisystemic inflammatory disorder that has an unclear association with cognitive dysfunction. This Critically Appraised Topic synthesizes the results from relevant […]

» Read more

Serious infection risk in children with psoriasis on systemic treatment: a propensity score matched population-based study.

Bookmark(0)

Psoriasis (PsO) is increasingly treated with systemic medications, yet their safety is not well characterized in children.We sought to estimate the 6-month risk of serious infections in children with PsO […]

» Read more

Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies.

Bookmark(0)

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world’s population. In this guideline, we focus the discussion on systemic, non-biologic medications for […]

» Read more

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Bookmark(0)

Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.1. To assess the relative drug survival […]

» Read more

What are the barriers to physical activity in patients with chronic plaque psoriasis?

Bookmark(0)

Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Despite recommendation that exercise is important for cardiorespiratory fitness, patients with psoriasis avoid participation in physical activities for reasons […]

» Read more
1 2 3 6